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ABSTRACT
Introduction: HIV-infected children and adolescents treated with highly active antiretroviral 
therapy (HAART) regimens that include a protease inhibitor (PI) can show significant 
improvements in clinical outcomes, nutritional status and quality of life. The study aimed to report 
nutritional and metabolic alterations for pediatric patients continuously exposed to HAART 
and for healthy controls for up to 1 year. Methods: Clinical, anthropometric, lipid profile and 
food intake data were collected prospectively over approximately 12-months for each patient. 
Results: Fifty-one individuals were studied, of these, 16 were healthy. After 12 months follow-
up, HIV-positive individuals remained below the healthy control group parameters. No change 
was observed concerning food intake. Triglyceride serum levels were higher in patients using 
protease inhibitor at the onset of the study [PI groups: 114 (43 - 336), and 136 (63 - 271) versus 
control group: 54.5 (20 - 162); p = 0.003], but after twelve months follow-up, only the group 
using protease inhibitor for up to two months presented higher values [140 (73 - 273) versus 67.5 
(33 - 117); p = 0.004]. HDL-cholesterol was lower in HIV-positive individuals [HIV-positive 
groups: 36 (27 - 58) and 36 (23 - 43); control 49.5 (34 - 69); p = 0.004]. Conclusions: HIV-infected 
children and adolescents treated with highly active antiretroviral therapy showed compromised 
nutritional parameters compared to a paired healthy control group. Individuals using protease 
inhibitor presented worse triglyceride serum levels compared to their healthy counterparts.
Keywords: Body composition. Dyslipidemia. Highly active antiretroviral therapy. 
HIV- positive children. Lipid profile. Nutritional status.
RESUMO
Introdução: Crianças e adolescentes infectadas pelo HIV e tratadas com terapia antirretroviral 
de alta potência (TAAP), que inclui inibidor de protease (IP) podem apresentar significante 
melhora clínica no estado nutricional e na qualidade de vida. O objetivo é relatar as alterações 
nutricionais e metabólicas em pacientes pediátricos expostos a TAAP e controles saudáveis 
durante 1 ano. Métodos: O perfil clínico, antropométrico e lipídico, bem como dados da 
ingestão alimentar foram coletados prospectivamente durante aproximadamente 12 meses. 
Resultados: Cinquenta e um indivíduos foram estudados. Dezesseis eram saudáveis. Após 12 
meses de acompanhamento, indivíduos HIV-positivo permaneceram abaixo dos parâmetros 
do grupo controle saudável. Nenhuma mudança foi observada em relação à ingestão alimentar. 
Níveis séricos de triglicerídeos foram maiores em pacientes usando inibidor de protease no 
começo do estudo [IP grupo: 114 (43 - 336), e 136 (63 - 271) versus grupo controle: 54.5 
(20 - 162); p = 0.003], porém após doze meses de acompanhamento, apenas o grupo que 
recebeu inibidor de protease por não mais do que dois meses apresentou maiores valores [140 
(73 - 273) versus 67.5 (33 - 117); p = 0.004]. HDL-colesterol foi menor nos indivíduos HIV-
positivos [grupo HIV-positivo: 36 (27 - 58) e 36 (23 - 43); controle 49.5 (34 - 69); p=0.004]. 
Conclusões: Crianças e adolescentes infectadas pelo HIV e tratadas com terapia antirretroviral 
de alta potência tiveram seus parâmetros nutricionais comprometidos quando comparados 
com o pareado grupo controle. Indivíduos usando inibidor de protease apresentaram piores 
níveis séricos de triglicerídeos quando comparados com os saudáveis. 
Palavras-chaves: Composição corporal. Dislipidemia. Terapia antirretroviral de alta potência. 
Crianças HIV-positivas. Perfil lipídico. Estado nutricional.
HIV-infected children and adolescents treated 
with highly active antiretroviral therapy (HAART) 
regimens that include a human immunodeficiency 
virus (HIV) protease inhibitor (PI) can exhibit 
significant improvements in clinical outcomes, 
nutritional status and quality of life1. HAART 
generally includes three or more antiretroviral 
agents used in combination. These drugs are 
selected from any of three well-recognized classes: 
nucleoside reverse transcriptase inhibitors (NRTI), 
non-nucleoside reverse transcriptase inhibitors 
(NNRTI), or protease inhibitors (PI). However, 
HAART has also been associated with certain 
undesirable side effects, including gastrointestinal 
intolerance, high pill burden, mitochondrial 
toxicities and lipodystrophy.
The lipodystrophy syndrome has been clinically 
characterized by fat redistribution with an associated 
range of metabolic abnormalities2. The physical 
features include clinical evidence of at least one 
of the following: fat wasting (lipoatrophy) of the 
face, extremities, or buttocks and fat accumulation 
(lipohypertrophy) in the abdomen or over the 
dorsocervical spine. The metabolic features include at 
least one of the following: fasting hypertriglyceridemia 
and/or hypercholesterolemia, fasting C-peptide 
level elevation and evidence of abnormal glucose 
metabolism, including disorders ranging from 
abnormal fasting glucose levels to diabetes mellitus2-4.
Although published studies have yielded valuable 
data on the characterization of lipodystrophy 
syndrome and metabolic changes and its association 
with PI-containing antiretroviral therapy among 
children and adolescents worldwide, very little data 
exist in Brazil concerning nutritional status, quality 
of life and lipid profile5,6 after one year of HAART.
This study reports longitudinal clinical data for 
pediatric patients continuously exposed to HAART 
regimens and healthy controls groups for up to 1 
year, and describes the nutritional and lipid profiles 
compared in both groups.
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METHODS
RESULTS
Tremeschin MH et al - Dyslipidemia in pediatric HIV-positive patients
Children attending the Pediatric Outpatient HIV Clinic at 
our center were studied. Every consecutive child who came to 
the teaching hospital of the School of Medicine of Ribeirão Preto, 
University of São Paulo, Brazil, over two years (2006 to 2007) was 
recruited and submitted to an interview to check their availability and 
inclusion criteria for participation. The institutional research ethics 
committee approved the research protocol and all the patients and 
their parents or legal guardians provided written informed consent to 
participate. The participants were divided into 4 groups of patients on 
the basis of the type of HAART being used: group 1, patients using 
nucleoside reverse transcriptase inhibitors or non-nucleoside reverse 
transcriptase inhibitors; group 2, patients using protease inhibitor 
(PI) for more than two months; group 3, patients using protease 
inhibitor for up to two months; and group 4, paired HIV-negative 
healthy children and adolescents.
The inclusion criteria were the ability to complete the 
anthropometry and absence of liver disease, chronic or acute 
pancreatitis, renal failure, or diarrhea that could interfere in the 
development of the child and their nutritional status. None of 
the patients was receiving vitamin supplementation or appetite 
stimulants and all were clinically stable.
The HIV-negative children and adolescents were selected from 
a Health Center in Ribeirão Preto, Brazil, and were paired for age 
and sex.
Data was collected prospectively over 12-months, for each 
patient. All HIV-positive patients received medical care according to 
the Pediatric Outpatient HIV Clinic protocol. Data obtained from 
medical records included age, sex, complete antiretroviral therapy 
history, Centers for Disease Control and Prevention classification, 
CD4+ T lymphocyte counts and HIV-1 RNA levels.
Hypercholesterolemia was defined as a total fasting cholesterol 
level higher than 200mg/dl and a low-density lipoprotein cholesterol 
level higher than 130mg/dl. Hypertriglyceridemia was defined as 
a fasting triglyceride level above 140mg/dl7. Hyperlipidemia was 
defined as serum triglycerides ≥ 140mg/dl and/or serum cholesterol 
≥ 200mg/dl.
Laboratory studies of total serum cholesterol and triglycerides 
were performed by commercial laboratories as part of routine clinical 
care. Lipid measurements were based on fasting blood samples.
The nutritional assessment of these children occurred at uniform 
intervals, generally every 6 months, as mandated by the service 
protocol of patients, and the data were recorded in a database 
(SPSS 15.0).
Weight and height were assessed according to the method 
described by Heymsfield et al8 and determined by a dietitian who 
was trained to take all measurements. The reference data of the 
World Health Organization/National Center for Health Statistics/
Centers for Disease Control and Prevention9 was used. For the 
estimation of fat-free mass and total body water, a bioelectrical 
impedance technique (BIA) was applied at the same time the weight 
was measured10. The midarm circumference, waist circumference, 
subscapular skinfold and triceps skinfold were also measured 
to reflect lean body mass and fat11. Body mass index (BMI) was 
calculated by the standard formula using height and weight and 
plotted on CDC BMI-for-age curves for 2 to 20 years of age for girls 
and boys12. Weight, height and BMI values were converted to age- 
and sex-adjusted Z scores using EPI INFO® software program and 
individuals < - 2 standard deviation for weight for age and or height 
for age were considered malnourished.
Usual dietary intake was assessed by an adapted semi quantitative 
food-frequency questionnaire. Individuals were asked to report 
which foods they had eaten during the preceding three months 
based on a fixed list. The standard portion sizes were presented to 
the respondent, who was asked how many times the portion size was 
eaten. The standard portion sizes for each food were those reported 
in a previous study13,14. Respondents were asked to report their 
consumption as daily, weekly, monthly and rarely. Nutrient intakes 
associated with each pattern of food consumption were determined 
according to Dietsys software.
Quality of life was assessed by Autoquestionnaire de qualité de 
vie enfant imagé (AUQEI questionnaire)15 which was validated 
by Assumpção Jr et al16. It is a generic tool applied to children 
aged between 4 and 12 years-old, based on children’s subjective 
perspective of satisfaction regarding function, family, entertainment 
and autonomy. Values above 48 are indicative of good quality of life.
Statistical analyses
Continuous variables with normal distribution were expressed 
as mean ± standard deviation; in this case, comparison across 
groups was performed by analysis of variance (Post Hoc) and the 
non-paired t test. The nonparametric Kruskal-Wallis test was used 
to compare variables with non-normal distribution, which were 
expressed as median and range. The Wilcoxon test was used to 
compare longitudinal variables; this tests whether the distribution 
of two paired variables in two related samples is the same and takes 
into account the magnitude of the differences between two paired 
variables. The Χ2 test or Fisher exact test was used to compare 
frequency distributions across groups. Linear regression analysis 
was used to determine whether alterations in weight and body 
composition were associated with changes in quality of life, since 
most commonly, linear regression refers to a model in which the 
conditional mean of y given the value of X is an affine function of X. 
Analysis of covariance (ANCOVA) was also applied for energy intake 
in two moments, adjusted for age and weight, to test the hypothesis 
that age and weight could interfere in the results of energy intake. P 
< 0.05 was considered statistically significant.
Fifty-one children and adolescents agreed to participate and met 
the criteria for inclusion in this study. They were distributed into four 
groups: group 1 (n = 17), group 2 (n = 9), group 3 (n = 9) and group 
4 (n = 16). Stavudine, as part of a backbone NRTI regimen, and 
PI use, have both been associated with lipodystrophy syndrome17; 
however, in the present study, no statistical difference was verified in 
the proportion of individuals receiving stavudine among the groups 
(at the onset of the study: G1 17.6%, G2 33.3%, G3 33.3% p = 0.57; 
after twelve months: G1 23.5%, G2 22.2%, G3 33.3% p = 0.82). 
At the onset of the study, the median duration of PI therapy was 
27 months for group 2 and 1 month for group 3, and the median 
duration of prior NRTI or NNRTI therapy was 86 and 84 months, 
respectively. No significant differences between groups 1, 2 and 3 
with respect to viral loads were noted at any time point, but CD4 cell 
counts and the CD4/CD8 ratio were worse for group 3 at the onset 
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of the study compared to group 2. Eight (47%) out of 17 patients in group 
1 had prior AIDS, whereas five (55%) out of nine patients in group 2 and 
seven (78%) out of nine patients in group 3 had prior AIDS; this difference 
was not statistically significant (p > 0.05). No significant differences 
between any of the groups with respect to age and sex were observed 
(54.9% male versus 45.1% female, p = 0.32). Quality of life was similar 
between groups at all time points, according to the AUQEI questionnaire. 
There were also no statistical differences between groups 1, 2 and 3 
concerning HIV infection classification at any time point. The demographic 
and clinical data for all patients are presented in Tables 1 and 2.
Triglycerides serum levels were higher in patients using protease 
inhibitor compared to healthy controls at the onset of the study, but 
after twelve months follow-up, only group 3 had higher values and HDL 
cholesterol serum levels were lower in group 1 and 3 compared to group 
4 (Table 1). In spite of that there was no statistical differences between 
the groups concerning patients who exhibited hyperlipidemia: 12% (2) 
of patients in group 1, 33.3% (3) of patients in group 2, 44.4% (4) of 
patients in group 3, exhibited hyperlipidemia at any time point; 18.7% 
(3) and 6.2% (1) of patients exhibited hyperlipidemia at the study onset 
and after twelve months follow-up, respectively, for group 4.
At the beginning of the study, healthy controls subjects presented 
greater weight, height/age adequacy, Z scores for weight and height 
and triceps and subscapular skinfold thickness adequacy compared 
to HIV-positive individuals. Concerning body mass index adequacy, 
groups using protease inhibitor presented lower values compared to 
groups 1 and 4, but with statistically significant results only for group 2 
(Table 2). After twelve months follow-up, group 2 showed the worst 
values for almost all the anthropometric parameters and group 4, the 
best values compared to HIV-positive individuals (Table 2).
At the onset of the study, malnourished individuals constituted 5.9% 
of group 1, 44.4% of group 2, 33.3% of group 3 and 0% of group 4 (p = 
0.007). Individuals in PI groups presented greater malnourishment than 
individuals in group 4 (p < 0.05); and group 2 presented worse values 
compared to group 1 (p = 0.03) and group 4 (p = 0.009). After twelve 
months follow-up, only group 2 showed an increase in the number of 
malnourished individuals (55.5%). In group 1, overweight individuals 
constituted 11.8% at the onset of the study, while overweight individuals 
constituted 6.2% of group 4 at the end of the study. At the onset of the 
study, obese individuals constituted 5.9% and 12.5% of groups 1 and 4, 
respectively. A decrease in the rate of obesity occurred in group 4 by the 
end of the study (6.2%). 
Bioelectrical impedance analyses were unable to detect any differences 
between the groups at any point during the study (Table 3).
Energy and macronutrient intakes were similar between the groups 
at all time points during the study, but a higher lipid intake (% of energy 
intake) occurred compared to the recommended intake in all groups. The 
mean energy intake at the onset of the study and at the end of study was, 
respectively, 2,413kcal (1,586 - 5,806) and 2,148kcal (1,289 - 4,166). The 
mean percentage of lipid calories at the onset and end of the study was, 
respectively, 37.8% (28.6 - 49.2) and 38.5% (28 - 48.6). Age and weight 
did not interfere with the energy intake results, according to ANCOVA 
analyses (at the onset: age p = 0.39, weight p = 0.72; at the end: age 
p = 0.94, weight p = 0.49).
An increase in CD4 cell count occurred in group 1 after twelve 
months follow-up (p = 0.044). Clinical improvement was not observed 
in groups 2 and 3 (p > 0.05 for all parameters).
An increase in weight (p = 0.002), height (p = 0.001), waist 
circumference (p = 0.008), triceps skinfold thickness (p = 0.036), 
subscapular skinfold thickness (p = 0.003), mid-arm-muscle 
circumference (p = 0.006), height/age ratio (p = 0.018) and lean body 
mass (p = 0.001) occurred in group 1 after twelve months follow-up.
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An increase in weight (p = 0.008), height (p = 0.008), triceps 
skinfold thickness (p = 0.035), subscapular skinfold thickness 
(p = 0.034) and lean body mass (p = 0.008) also occurred in group 
2 after twelve months follow-up.
Group 3 showed an increase in weight (p = 0.008), height 
(p = 0.008), subscapular skinfold thickness (p = 0.034) and lean 
body mass (p = 0.017) after twelve months follow-up.
Group 4 also showed progress in nutritional status, with an 
increase in weight (p = 0.003), height (p = 0.001), height/age 
index (p = 0.008), Z score for height (p = 0.01), body mass index 
(p = 0.032), mid-arm-muscle circumference (p = 0.008) and lean 
body mass (p = 0.002) after twelve months follow-up.
TABLE 3 - Bioelectrical impedance analyses of children and adolescents distributed according to type and time of antiretroviral 
therapy (ART) at the beginning of the study and after twelve months follow-up.
Parameters Group 1(n = 17) Group 2(n = 9) Group 3(n = 9) Group 4(n = 16) p-value
At the beginningof study     
lean body mass (Kg) 24.1 (14.3–39.3) 24.2 (12.6–34.5) 20.1 (12.7–36.4) 28 (14.2–49.3) 0.544
fat mass (Kg) 6.6 (3.1–16.3) 5.3 (1.9–11.1) 4.9 (3.8–15.1) 6.9 (1.8–24.5) 0.444
body cell mass (Kg) 11.95 (7.6–19.3) 11.1 (6.4–16.4) 9.7 (6.5–18.2) 13.95 (7–24.1) 0.460
total body water (Liters) 18.2 (10.6–28.8) 17.7 (10.2–25.1) 15.2 (9.6–27.3) 20.45 (11.5–34.9) 0.431
After 12 months of study     
lean body mass (Kg) 26.6 (15.7–44.9) 28.4 (14–35.9) 23 (15.5–46.1) 32.55 (15.5–48) 0.636
fat mass (Kg) 7.1 (3.9–13.7) 4.9 (2.6–15.1) 5.75 (3.2–13.3) 7.05(2.7–22.9) 0.588
body cell mass (Kg) 13 (8.2–22.8) 13.1 (7.1–17.5) 11.35 (7.9–23.9) 15.6 (7.9–25.8) 0.489
total body water (Liters) 20 (11–33) 21(11–25.3) 17.15 (11.9–34.2) 23.9 (12.2–36) 0.608
No differences were observed concerning food intake after twelve 
months follow-up in groups 1, 2 and 3 (p > 0.05 for all parameters). 
Group 4 presented a decrease in food intake in relation to energy 
(p = 0.020), protein (p = 0.030) and carbohydrate (p = 0.044).
After twelve months follow-up, no change was observed 
concerning the lipid profiles in all groups (p > 0.05 for all parameters), 
except for an increase in HDL cholesterol in group 4. 
Linear regression analysis showed that an increase in fat mass in 
HIV-positive individuals is associated with quality of life (p = 0.026; 
adjusted for age and sex p = 0.042; adjusted for time using protease 
inhibitor PI p = 0.047; adjusted for time in antiretroviral therapy p = 0.034) 
(Table 4). No other variable was statistically associated with quality of life.
TABLE 4 - Regression coefficients β 1 (95% confidence interval) for the 
difference in quality of life according to fat mass alteration in HIV positive 
children after twelve months follow-up.
 Alteration in quality of life
Difference in fat mass β CI 95% p
Model 1* 0.406 0.195 - 2.848 0.026
Model 2** 0.410 0.059 - 3.018 0.042
Model 3 *** 0.041 0.025 - 3.049 0.047
Model 4 † 0.433 0.129 - 3.104 0.034
*Model 1: crude analysis, **Model 2: adjusted for age and sex, ***Model 3: model 2 + 
Time using protease inhibitor,  †Model 4: model 2 + time using antiretroviral therapy.
DISCUSSION
Analysis of the data obtained showed that clinically stable HIV-
positive children and adolescents still present greater compromise 
regarding nutritional status compared to healthy controls paired for 
age, sex and quality of life, in the HAART era. The most compromised 
were the individuals using protease inhibitor. Despite adequate 
nutritional improvement after twelve months follow-up, HIV-positive 
individuals remained below the healthy control group parameters. 
An increase in fat mass in HIV-positive individuals improves quality 
of life predictions. No change was observed concerning food intake 
and only the group using NRTI and/or NNRTI showed a statistically 
significant increase in CD4 cell count after twelve months follow-
up. Triglyceride serum levels were higher in patients using protease 
inhibitor compared to healthy controls at the onset of the study, but 
after twelve months follow-up, only the group using PI for up to 
two months presented triglyceride serum levels higher than healthy 
controls, while HDL cholesterol serum levels were lower in groups 
1 and 3 compared to group 4. A proportion of hyperlipidemia 
occurred in individuals using protease inhibitor, though this was 
not statistically significant. Despite the small sample size, the results 
obtained were similar to those reported by Aldrovandi et al in a larger 
cross-sectional multicenter study in the United States18.
Despite worse nutritional status compared to controls, HIV-
positive individuals presented an increase in weight, height, fat mass 
and fat-free mass after twelve months follow-up. Longitudinal follow-
up monitoring HIV-positive children with HAART also showed 
an increase in lean mass19. The study by Verweel et al indicates that 
virology respondent children with HIV-infection show an increase 
in height and weight following the initiation of HAART20.
It seems that HAART had a positive effect on height and weight 
in the children and adolescents with HIV-infection in this study, 
though not sufficient to achieve healthy control values. This effect 
was sustained for at least 12 months (48 weeks) and can last up to 
96 weeks according to Verweel et al20. These sustained effects on fat 
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mass may positively influence the child’s quality of life, as shown 
by the present results and will predictably contribute to improved 
prognosis. The positive effect of HAART on nutritional parameters 
has been extensively reported21-25.
Group 4 showed the best values for z scores compared to the 
HIV-positive groups. After twelve months follow-up, only group 4 
showed an increase in the height-for-age Z score. In contrast, group 2 
presented more malnourished individuals compared to groups 1 and 
4 at the onset of the study. After twelve months follow-up, only group 
2 presented an increase in the number of malnourished individuals, 
which can be attributed to poorer clinical evolution in one patient. 
Similar results were reported by Verweel et al20.
In the present study, triceps and subscapular skinfold thickness 
and mid-arm muscle circumference showed no detectable statistical 
differences, comparing individuals using NRT/NNRT and PIs, and 
fat redistribution was not an important feature in these individuals, 
corroborating the results obtained by Santos et al26. Melvin et al27 
suggested that dyslipidemia occurs prior to body changes in the 
lipodystrophy syndrome, especially in individuals in Tanner stages 
1 and 2. This study did not analyze Tanner classification stage, but 
the median age of the children was compatible with stages 1 and 2. 
Metabolic abnormalities and fat redistribution are more likely to 
occur in post-pubertal children, especially those who are receiving 
protease inhibitor treatment28-30.
The period of follow-up and age were statistically similar between 
the groups, but might have affected the results, since the control 
group presented 14.5 months of follow-up compared to 14, 11 and 
10 months for groups 1, 2 and 3, respectively. Since statistically 
significant differences for weight, height, triceps and subscapular 
skinfold thickness were verified at the onset of the study, this shows 
that HIV-positive individuals continue to present poorer nutritional 
parameters than the healthy control group.
In the present study, HIV-infected individuals showed worse 
nutritional evolution compared to healthy controls, despite similar 
food intake. HIV-1-infected children in developed countries present 
similar birth weights compared to non-infected groups, but quickly 
diverge in both weight and height within the first few months of life31. 
This fact is difficult to explain because in children who fail to gain 
weight, identifying a single factor, which, when corrected, results 
in normal growth in the course of HIV infection is uncommon. 
Evidence of significantly less lean body mass (as assessed by midarm 
circumference and triceps skinfold thickness) has been verified 
among very young HIV-infected children compared to control 
children of similar age32. At present, the pathogenesis of weight loss 
or growth failure in HIV infection is largely speculative. Many factors, 
including poor oral intake, malabsorption, and hypermetabolism 
may be involved33. Disturbances in the growth hormone insulin-like 
growth factor axis that have been described in HIV infection could 
also play a role in the growth and body composition abnormalities 
observed here34.
The fact that there were more malnourished individuals among 
HIV-infected children compared to controls in the present study 
suggests that the nutritional characteristics of Brazilian HIV-infected 
children may not become similar to their uninfected counterparts as 
they become healthier with HAART, a fact that is in disagreement 
with the results of some studies20,35. 
Many reports regarding clinically evaluated lipodystrophy 
syndrome suggest that peripheral atrophy is often accompanied 
by an increase in central obesity in HIV-infected individuals using 
HAART. In the present study, waist circumference does not permit 
precise characterization of any increase in central obesity in HIV-
positive individuals. It is possible that waist circumference cannot 
easily distinguish changes in fat from lean and may not be suitable 
for this purpose in children. 
In contrast to the increase in the body mass index (BMI) in adults 
on HAART, BMI did not increase in all children effectively treated 
with HAART after twelve months follow-up in the present study. 
These result corroborates similar findings reported by Verweel et al20. 
It is possible that BMI increases more in children with an advanced 
stage of infection and poor nutritional status at baseline36.
Bioelectrical impedance was unable to detect any differences 
between the groups. BIA has been used to assess body composition in 
HIV-infected children, but interpretation of the results is difficult due 
to the lack of standards for children37-39. The accuracy of bioelectric 
impedance may vary not only in relation to the equations used, 
but by sex and percentage of body fat40. In addition, BIA measures 
only whole-body fat and lean body mass, thus it cannot diagnose 
abnormalities in fat redistribution and may be inaccurate in the 
setting of lipodystrophy41.
Food intake was similar between the groups and no changes were 
observed after twelve months follow-up, except for a decrease in 
energy, protein and carbohydrate intake in the control group. Despite 
this fact, a higher proportion of lipid intake than carbohydrate was 
verified in all groups.
Decreased nutrient intake is not encountered in children with 
HIV infection. The dietary intake among children with HIV infection 
is reported to be equal to or greater than those in non-infected 
children42 and additional variables, such as metabolic abnormalities, 
could be involved in lipodystrophy syndrome43.
Nutritional concerns in HIV-infected children have evolved, from 
wasting to obesity and insulin resistance. Excessive caloric intake and 
a shift in dietary composition toward lipids suggest that continued 
dietary monitoring in HIV-infected children is important to avoid 
increased risk of cardiovascular disease.
The present study showed that an increase in fat mass is associated 
with better quality of life. The AUQEI questionnaire seemed to be 
appropriate in pediatric and adolescent populations with HIV44,45. 
Preliminary evidence in pediatric HIV-1 research suggests that 
combination antiretroviral therapies have a positive effect on mean 
weight, height, growth velocity, appetite, and well-being21,23,45,46.
Studies on the tolerability and efficacy of PI containing regimens 
have mentioned alterations in serum lipids ranging from dyslipidemia 
in 20% to 50% of children on single PI to > 90% on dual PI containing 
regimens45,47-49. The present data showed a lower proportion of 
hyperlipidemia compared to the study by Taylor et al50, who 
reported 58.3% and the study by Werner et al, who verified 88.3%51. 
In addition, the proportion of hyperlipidemia among HIV-positive 
individuals was similar to the healthy control group, suggesting that 
the HAART regimen alone could not be associated with an increased 
risk of dyslipidemia. Taylor et al50 also confirmed that some patients 
using protease inhibitor may not develop dyslipidemia. 
Genetic, pharmacokinetic, virological and/or immunological 
factors may protect these children after longer treatment duration, 
the differences could be associated with drug dosing and may be 
more pronounced in children with higher PI levels52.
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The study failed to detect higher dyslipidemia in the group 
using PIs, and the the occurrence of hypertrygliceridemia among 
HIV-positive individuals from groups 2 and 3 could have preceded 
the use of protease inhibitor53. Although initial reports implicate 
protease inhibitors, more recent studies have suggested that 
nucleoside analogues could play a role in the development of 
lipodystrophy syndrome, including dyslipidemia2,54.
The study also failed to detect any association between PI 
duration and dyslipidemia. Cheseaux et al55 and Krause et al also 
reported no significant increase even after 24 and 30 months of 
antiretroviral therapy56. The stabilizing relation with extended 
durations of PI usage may explain why most cross-sectional studies 
have failed to detect this association. 
The study has limitations. The assessment of the physical 
abnormalities of lipodystrophy was not possible, because assessment 
of the phenotypic manifestations of lipodystrophy with physical 
examinations is inherently subjective and may differ among different 
providers. In addition, sex differences in growth and body composition 
in children in response to infection have been described39. 
The study design does not permit any conclusions regarding 
whether PI alone may be associated with dyslipidemia or whether 
a potentiating effect occurs when combining PI with nucleoside 
inhibitors. Processes that lead to changes in metabolic parameters 
are likely to be multifactor, and dyslipidemia occurs in patients 
who have never received PI57-59. Furthermore, the fact that patients 
were not randomized to PI therapy and that the study was based 
on a small number of HIV-infected children must be taken into 
account. 
Since body composition shows a wide variation in growing 
children according to age, sex and pubertal status, inter-individual 
variability was minimized by comparing each HIV-infected patient 
with a matched healthy control. In addition, each child was used as his 
or her own control by capturing data after twelve months follow-up.
Further studies, mainly longitudinal cohort studies, are required 
to precisely describe the time course of body-composition changes 
in HIV-infected children and, because they will probably survive for 
longer periods in adulthood, the long-term risks for the development of 
premature cardiovascular disease attributable to prolonged dyslipidemia 
associated with antiretroviral therapy warrant additional studies.
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